Axsome Therapeutics Announces FDA Approval of AUVELITY™ Viés de alta

Axsome Therapeutics, Inc.NASDAQ

Descrição

⋅ 19 de Ago de 2022 17:00

AXSM: Axsome Therapeutics, Inc.
2022-08-19 Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

Beyond Technical Analysis

Mais